- Pediatric Emergency Medicine
Clinical Assistant Professor, Emergency Medicine
Board Certification: American Board of Pediatrics, Pediatric Emergency Medicine (2023)
Board Certification, American Board of Pediatrics, Pediatric Emergency Medicine (2023)
Residency: Stanford University Pediatric Residency at Lucile Packard Children's Hospital (2018) CA
Fellowship: Seattle Children's Emergency Medicine Fellowship (2022) WA
Board Certification: American Board of Pediatrics, Pediatrics (2017)
Medical Education: Creighton University School of Medicine Registrar (2014) NE
Additional Clinical Info
Pediatric Emergency Medicine Didactics and Simulation: JumpSTART Secondary Triage for Mass Casualty Incidents.
2023; 15 (6): e40009
Mass casualty incidents (MCI), particularly involving pediatric patients, are high-risk, low-frequency occurrences that require exceptional emergency arrangements and advanced preparation. In the aftermath of an MCI, it is essential for medical personnel to accurately and promptly triage patients according to their acuity and urgency for care. As first responders bring patients from the field to the hospital, medical personnel are responsible for prompt secondary triage of these patients to appropriately delegate hospital resources. The JumpSTART triage algorithm (a variation of the Simple Triage and Rapid Treatment, or START, triage system) was originally designed for prehospital triage by prehospital providers but can also be used for secondary triage in the emergency department setting. This technical report describes a novel simulation-based curriculum for pediatric emergency medicine residents, fellows, and attendings involving the secondary triage of patients in the aftermath of an MCI in the emergency department. This curriculum highlights the importance of the JumpSTART triage algorithm and how to effectively implement it in the MCI setting.
View details for DOI 10.7759/cureus.40009
View details for PubMedID 37425609
View details for PubMedCentralID PMC10322648
Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine
CURRENT ALLERGY AND ASTHMA REPORTS
2021; 21 (3): 18
Anaphylaxis is a severe, life-threatening, systemic allergic reaction that should be recognized and treated promptly. Intramuscular (IM) epinephrine is the first-line treatment for anaphylaxis and there are no absolute contraindications to its use. Despite its established track record of efficacy and safety, physicians and patients face barriers in the recognition and treatment of anaphylaxis, including the maintenance and appropriate use of epinephrine auto-injectors. This has led to investigation into potential alternatives to IM epinephrine administration in anaphylaxis.This review investigates the current standard of care in the treatment of anaphylaxis, barriers to IM epinephrine use, and alternative therapies under investigation for administration in anaphylaxis. Alternative routes under investigation include intranasal, sublingual, inhaled, and needle-free intramuscular administration of epinephrine. There are currently numerous investigational alternatives to IM epinephrine therapy which could hold promise as future effective treatments in the emergent management of anaphylaxis.
View details for DOI 10.1007/s11882-021-00994-0
View details for Web of Science ID 000626588000005
View details for PubMedID 33666759
View details for PubMedCentralID 3500036